Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Fletcher

Showing results (311-320 of 326) with videos related to

Pageof 33
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 17, 2021
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose RifapentineAnthony T Podany, Michelle Pham, Erin Sizemore, et al.
JAMA Network Open|March 16, 2022
Efficacy of Losartan in Hospitalized Patients With COVID-19-Induced Lung Injury: A Randomized Clinical TrialMichael A Puskarich, Nicholas E Ingraham, Lisa H Merck, et al.
Nature Communications|January 19, 2023
Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19Kara W Chew, Carlee Moser, Eric S Daar, et al.
Nature Communications|August 22, 2022
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19Kara W Chew, Carlee Moser, Eric S Daar, et al.
JAMA Network Open|April 26, 2023
Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical TrialsRachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.
Annals of Internal Medicine|April 17, 2023
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19Teresa H Evering, Kara W Chew, Mark J Giganti, et al.
Open Forum Infectious Diseases|September 22, 2025
Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody TherapyRinki Deo, Manish C Choudhary, Owen T Glover, et al.
Medrxiv : the Preprint Server for Health Sciences|September 21, 2021
Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody TherapyManish C Choudhary, Kara W Chew, Rinki Deo, et al.
Nature Microbiology|October 27, 2022
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trialManish C Choudhary, Kara W Chew, Rinki Deo, et al.
Elife|February 21, 2022
Pseudohypoxic HIF pathway activation dysregulates collagen structure-function in human lung fibrosisChristopher J Brereton, Liudi Yao, Elizabeth R Davies, et al.
Pageof 33

Showing results (311-320 of 326) with videos related to

Sort By:
Pageof 33
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 17, 2021
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose RifapentineAnthony T Podany, Michelle Pham, Erin Sizemore, et al.
JAMA Network Open|March 16, 2022
Efficacy of Losartan in Hospitalized Patients With COVID-19-Induced Lung Injury: A Randomized Clinical TrialMichael A Puskarich, Nicholas E Ingraham, Lisa H Merck, et al.
Nature Communications|January 19, 2023
Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19Kara W Chew, Carlee Moser, Eric S Daar, et al.
Nature Communications|August 22, 2022
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19Kara W Chew, Carlee Moser, Eric S Daar, et al.
JAMA Network Open|April 26, 2023
Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical TrialsRachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.
Annals of Internal Medicine|April 17, 2023
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19Teresa H Evering, Kara W Chew, Mark J Giganti, et al.
Open Forum Infectious Diseases|September 22, 2025
Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody TherapyRinki Deo, Manish C Choudhary, Owen T Glover, et al.
Medrxiv : the Preprint Server for Health Sciences|September 21, 2021
Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody TherapyManish C Choudhary, Kara W Chew, Rinki Deo, et al.
Nature Microbiology|October 27, 2022
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trialManish C Choudhary, Kara W Chew, Rinki Deo, et al.
Elife|February 21, 2022
Pseudohypoxic HIF pathway activation dysregulates collagen structure-function in human lung fibrosisChristopher J Brereton, Liudi Yao, Elizabeth R Davies, et al.
Pageof 33